Literature DB >> 32247292

S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC) - short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow-up, prevention and occupational disease.

Ulrike Leiter1, Markus V Heppt2,3, Theresa Steeb2,3, Teresa Amaral1, Andrea Bauer4, Jürgen C Becker5, Eckhardt Breitbart6, Helmut Breuninger1, Thomas Diepgen7, Thomas Dirschka8, Thomas Eigentler1, Michael Flaig2, Markus Follmann9, Klaus Fritz10, Rüdiger Greinert6, Ralf Gutzmer11, Uwe Hillen12, Stephan Ihrler13, Swen Malte John14, Oliver Kölbl15, Klaus Kraywinkel16, Christoph Löser17, Dorothee Nashan18, Seema Noor1, Monika Nothacker19, Christina Pfannenberg20, Carmen Salavastru10, Lutz Schmitz21, Eggert Stockfleth21, Rolf-Markus Szeimies22, Claas Ulrich23, Julia Welzel24, Kai Wermker25, Claus Garbe1, Carola Berking2,3.   

Abstract

Actinic keratoses (AKs) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guidelines for actinic keratosis and cutaneous squamous cell carcinoma were developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guidelines are aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AKs and cSCC. The guidelines are also aimed at affected patients, their relatives, policy makers and insurance funds. In the second part, we will address aspects relating to epidemiology, etiology, surgical and systemic treatment of cSCC, follow-up and disease prevention, and discuss AKs and cSCC in the context of occupational disease regulations.
© 2020 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.

Entities:  

Mesh:

Year:  2020        PMID: 32247292     DOI: 10.1111/ddg.14072

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  7 in total

Review 1.  Hide-and-seek: Neurotropic squamous cell carcinoma of the periorbital region - a series of five cases and review of the literature.

Authors:  Evi M Morandi; Tina Rauchenwald; Petra Puelzl; Bernhard W Zelger; Bettina G Zelger; Benjamin Henninger; Gerhard Pierer; Dolores Wolfram
Journal:  J Dtsch Dermatol Ges       Date:  2021-11       Impact factor: 5.231

2.  Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial.

Authors:  Theresa Steeb; Anja Wessely; Dagmar von Bubnoff; Thomas Dirschka; Konstantin Drexler; Conrad Falkenberg; Jessica C Hassel; Kinan Hayani; Svea Hüning; Katharina C Kähler; Sigrid Karrer; Christian Krammer; Ulrike Leiter; Diana Lill; Enklajd Marsela; Andreas Meiwes; Dorothée Nashan; Suzan Nasifoglu; Lutz Schmitz; Judith Sirokay; Alexander Thiem; Jochen Utikal; Alexander Zink; Carola Berking; Markus V Heppt
Journal:  J Clin Med       Date:  2020-05-12       Impact factor: 4.241

Review 3.  Topical Pharmacotherapy for Actinic Keratoses in Older Adults.

Authors:  Piergiacomo Calzavara-Pinton; Irene Calzavara-Pinton; Chiara Rovati; Mariateresa Rossi
Journal:  Drugs Aging       Date:  2022-02-14       Impact factor: 3.923

4.  Case Report: Fluzoparib for multiple lines of chemotherapy refractory in metastatic cutaneous squamous cell carcinoma with BRCA2 pathogenic mutation.

Authors:  Xin Sun; Wenjuan Chen; Xiujuan Qu; Ying Chen
Journal:  Front Pharmacol       Date:  2022-08-12       Impact factor: 5.988

5.  Electrochemotherapy for the treatment of cutaneous squamous cell carcinoma: The INSPECT experience (2008-2020).

Authors:  Giulia Bertino; Ales Groselj; Luca G Campana; Christian Kunte; Hadrian Schepler; Julie Gehl; Tobian Muir; James A P Clover; Pietro Quaglino; Erika Kis; Matteo Mascherini; Brian Bisase; Giancarlo Pecorari; Falk Bechara; Paolo Matteucci; Joy Odili; Francesco Russano; Antonio Orlando; Rowan Pritchard-Jones; Graeme Moir; David Mowatt; Barbara Silvestri; Veronica Seccia; Werner Saxinger; Francesca de Terlizzi; Gregor Sersa
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

6.  A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis.

Authors:  Anja Wessely; Theresa Steeb; Franz Heppt; Annkathrin Hornung; Matthias D Kaufmann; Elias A T Koch; Frédéric Toussaint; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2021-02-19       Impact factor: 3.677

Review 7.  Integrin αE(CD103)β7 in Epithelial Cancer.

Authors:  Johanna C Hoffmann; Michael P Schön
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.